KAZIA THERAPEUTICS

Beyond Inhibition. Reprogramming Cancer Control.

2025 Annual General Meeting

26 March 2026

NASDAQ: KZIA | X: @KaziaTx

Agenda

- Chairman Opening Remarks
- CEO AGM Address
- CEO Update
  - Company Mission
  - July 2024 – June 2025 in Review
  - Subsequent Milestones
  - Pipeline Overview
  - Complimentary Layers of Cancer Control
  - Growth & Opportunity
  - Company Mission
- Resolution
- Closing Remarks

Chairman Opening Remarks

CEO AGM Address

Forward-Looking Statements

This presentation contains forward-looking statements, which can generally be identified as such by the use of words such as "may," "will," "estimate," "future," "forward," "anticipate," "plan," "expect," "explore," "potential" or other similar words. Any statement describing Kazia's future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements regarding: the timing for interim or final results and data related to Kazia's clinical and preclinical trials, or third-party trials evaluating Kazia's product candidates, timing and plans with respect to enrolment of patients in Kazia's clinical and preclinical programs, the potential benefits of NDL2, paxalisib, and EVT801, the potential results of combination studies of paxalisib and other collaborations, timing for any regulatory submissions or discussions with regulatory agencies, the potential market opportunity for NDL2, paxalisib and EVT801, and Kazia's strategy and plans with respect to its business and programs. Such statements are based on Kazia's expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties: associated with clinical and preclinical trials and product development, the risk that interim and preclinical data may not be reflective of final data, related to regulatory approvals, and related to the impact of global economic conditions, including disruptions in the banking industry. These and other risks and uncertainties are described more fully in Kazia's Annual Report, filed on Form 20-F with the SEC, and in subsequent filings with the SEC. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this presentation.

Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party studies, publications, surveys and other data to be reliable as of the date of this presentation, it has not independently verified, and makes no representations as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, no independent source has evaluated the reasonableness or accuracy of our internal estimates or research and no reliance should be made on any information or statements made in this presentation relating to or based on such internal estimates and research.

July 2024 – June 2025 in Review

Clinical

- Jul 2024 – Positive survival results reported from the Phase 2/3 GBM-AGILE study evaluating paxalisib in newly diagnosed glioblastoma.
- Sep 2024 – EVT801 clinical data presented at the Biennial Ovarian Cancer Research Symposium.
- Oct 2024 – Paxalisib + radiation clinical data presented at the ASTRO Annual Meeting.
- Jun 2025 – Phase 1b trial launched evaluating paxalisib in combination with immunotherapy in advanced breast cancer with first patient dosed.

Regulatory

- Nov 2024 – FDA Type-C meeting granted to discuss potential registrational pathway for paxalisib in glioblastoma.
- Dec 2024 – Regulatory update following FDA Type-C meeting outlining next steps for paxalisib development.

Scientific & External Validation

- Feb 2025 – Michael J. Fox Foundation grant awarded to evaluate paxalisib in Parkinson's disease.
- Jun 2025 – Preclinical research demonstrated paxalisib may overcome immunotherapy resistance in triple-negative breast cancer.

Strategic & Financial Execution

- Sep 2024 – Research collaboration with QIMR Berghofer announced to expand Kazia's translational oncology platform.
- Jan 2025 – $2m PIPE financing completed with existing investors.
- Mar 2025 – $1m sale of Cantrixil intellectual property completed, streamlining the portfolio.

Subsequent Milestones

2025
1 JULY – 30 SEPTEMBER

10 July
First TNBC patient receiving paxalisib combination regimen in Phase 1b trial achieves >50% reduction in CTCs

1 August
$2m private placement

12 September
Complete ex vivo disruption of large circulating CTC clusters in stage IV HER2-positive breast cancer with paxalisib monotherapy

2025
1 OCTOBER – 31 DECEMBER

7 October
First-in-class PD-L1 protein degrader program collaboration and in-licensing agreement with QIMR

18 November
Immune-complete response achieved in single-patient stage IV TNBC expanded access protocol

2 December
Pricing of $50m private placement of equity securities

2026
1 JANUARY - PRESENT

27January
Complete metabolic response in stage IV TNBC expanded access patient and 2 partial responses in metastatic TNBC Phase 1b study

30 January
PD-L1 degrader NDL2 demonstrates reversal of immune exhaustion, suppression of metastatic biology, and enhanced anti-tumor activity

16 March
Half-yearly financials filed

Pipeline Overview



IDH: Isocitrate dehydrogenase, DIPG: Diffuse Intrinsic Pontine Glioma, AT / RT : Atypical Teratoid Rhabdoid Tumor, CNS: central nervous system, VEGFR3: vascular endothelial growth factor receptor 3
*Product candidates (not approved)

KAZIA THERAPEUTICS

Complementary Layers of Cancer Control

Kazia is building a differentiated oncology portfolio aligned with the current shift in oncology, designed to overcome resistance in aggressive and immunotherapy-refractory cancers.

Paxalisib

Brain-penetrant dual PI3K / mTOR inhibitor with epigenetic and immunomodulatory activity

Epigenetic Pathway Modulation
- Inhibits PI3K-driven epigenetic regulators
- Reprograms metastatic and immune-suppressive tumor states

Enhances Immune Responsiveness
- Reduces tumor-driven immune suppression
- Improves sensitivity to immunotherapy and other targeted therapeutics

Clinically Validated Asset
- Evidence of clinical activity across CNS, breast cancer, and other solid tumors
- Fast Track, Orphan Drug, and Rare Pediatric Disease designations from US FDA

Strategic Backbone Across CNS & Breast Cancer
- Demonstrated relevance in high-unmet-need CNS tumors, including glioblastoma
- Expanding applicability into large breast cancer populations beyond TNBC
- Shared biological drivers enable multi-indication development and commercial scale

Safety and tolerability assessed in >550 patients to date
Phase 1b clinical study in TNBC ongoing

PD-L1 Protein Degrader Platform

First-in-class optimized PD-L1 protein degrader

NDL2 (Lead Compound) is First-in-Class PD-L1 Protein Degrader
- Target nuclear PD-L1 protein rather than transiently block receptor–ligand interaction
- Designed to overcome mechanisms of resistance to antibody-based checkpoint inhibitors

Epigenetic & Immune Reprograming of Resistant Tumors
- Targets tumor-intrinsic immune evasion not reached by existing immunotherapies
- Potential to restore immune sensitivity in refractory tumors

Platform & Combination Potential
- Potential broad applicability across solid tumors with rationale for combination with pathway inhibitors and cytotoxics
- Potential backbone for next-generation immuno-oncology regimens

Clear Development & Value Inflection Path
- Designed for rapid transition to first-in-human trials
- Multiple preclinical and translational milestones prior to clinical proof-of-concept

IND initiating studies commencing 2026

Growth & Opportunity

- We believe oncology innovation is driving exponential market growth
- New modalities are expanding therapeutic options for previously resistant cancers
- Kazia's pipeline is strategically aligned with these high-growth areas

Epigenetic Drugs

- **Current Market:** $15–20B
- **Projected 2034:** $80B+
- **Growth Driver:** Oncology applications

Immuno-Oncology

- **Current Market:** $83.34B
- **Projected 2035**: $409.44B
- **Growth Driver**: Increasing prevalence of cancer and need for innovative therapies, rising success of immunotherapies

Targeted Protein Degradation

- **2025 Market:** $699.3m
- **Projected 2033:** $3.26B
- **Growth Driver:** Prevalence of chronic disease conditions such as cancer, demand for novel treatments

1. Epigenetic Drugs Market 2. Immuno-Oncology Market 3. Targeted Protein Degradation Market

KAZIA THERAPEUTICS

Company Mission

Our mission is to redefine cancer treatment by moving beyond conventional pathway inhibition toward therapeutic reprogramming of cancer biology by targeting regulatory drivers of growth, immune escape, and relapse to deliver more durable outcomes for patients with the greatest unmet need.

Resolution – Re-election of Mr. Steven Coffey

That, Mr. Steven Coffey, who retires in accordance with Clause 21.1 of the Company's Constitution, being eligible, be elected as a director of the Company.

FOR	AGAINST	ABSTAIN	UNDIRECTED
1,050,366,764 99.65%	3,637,588 0.35%	1,289,127	46,016 0.00%

Closing Remarks

KAZIA
THERAPEUTICS

www.kaziatherapeutics.com
info@kaziatherapeutics.com